IRIS
CIPRIANI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.848
AS - Asia 7.466
EU - Europa 7.005
SA - Sud America 799
Continente sconosciuto - Info sul continente non disponibili 366
AF - Africa 110
OC - Oceania 26
Totale 29.620
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.599
SG - Singapore 3.311
IE - Irlanda 1.631
CN - Cina 1.527
RU - Federazione Russa 1.527
IT - Italia 827
HK - Hong Kong 759
TR - Turchia 720
BR - Brasile 673
VN - Vietnam 630
SE - Svezia 613
DE - Germania 599
UA - Ucraina 407
GB - Regno Unito 395
FR - Francia 354
FI - Finlandia 239
NL - Olanda 156
CA - Canada 150
IN - India 125
BD - Bangladesh 95
JP - Giappone 82
BE - Belgio 46
ZA - Sudafrica 43
AR - Argentina 42
MX - Messico 42
ES - Italia 41
PL - Polonia 33
LT - Lituania 30
ID - Indonesia 26
CZ - Repubblica Ceca 22
IQ - Iraq 20
PK - Pakistan 19
EC - Ecuador 18
VE - Venezuela 18
AU - Australia 17
CO - Colombia 17
KR - Corea 15
MA - Marocco 15
AT - Austria 14
EU - Europa 14
JM - Giamaica 14
SA - Arabia Saudita 14
JO - Giordania 13
MY - Malesia 11
CL - Cile 10
DZ - Algeria 10
GR - Grecia 10
NP - Nepal 10
PH - Filippine 10
TN - Tunisia 10
UZ - Uzbekistan 10
IL - Israele 8
NI - Nicaragua 8
PY - Paraguay 8
AL - Albania 7
AZ - Azerbaigian 7
CH - Svizzera 7
EG - Egitto 7
GT - Guatemala 7
KZ - Kazakistan 7
NZ - Nuova Zelanda 7
AE - Emirati Arabi Uniti 6
BO - Bolivia 6
HU - Ungheria 6
MK - Macedonia 6
RO - Romania 6
TH - Thailandia 6
HN - Honduras 5
KE - Kenya 5
LB - Libano 5
PE - Perù 5
TW - Taiwan 5
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
IR - Iran 4
PT - Portogallo 4
BB - Barbados 3
CI - Costa d'Avorio 3
GE - Georgia 3
HR - Croazia 3
KW - Kuwait 3
LU - Lussemburgo 3
MM - Myanmar 3
PR - Porto Rico 3
PS - Palestinian Territory 3
RS - Serbia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CW - ???statistics.table.value.countryCode.CW??? 2
ET - Etiopia 2
KG - Kirghizistan 2
LV - Lettonia 2
NG - Nigeria 2
NO - Norvegia 2
UY - Uruguay 2
YT - Mayotte 2
Totale 29.245
Salva come PNG Salva come JPEG
Città #
Singapore 1.783
Jacksonville 1.642
Dublin 1.624
Chandler 1.609
San Jose 1.437
Dallas 1.202
Ashburn 927
Hong Kong 747
Santa Clara 692
Boardman 579
Council Bluffs 448
Izmir 404
New York 354
The Dalles 335
Moscow 294
Nanjing 273
Wilmington 249
Beijing 235
Lawrence 235
Princeton 235
San Mateo 225
Ho Chi Minh City 205
Ann Arbor 196
Los Angeles 191
Lauterbourg 152
Milan 134
Hanoi 129
L'aquila 129
Amsterdam 120
Nanchang 100
Hefei 89
Dearborn 86
Woodbridge 86
São Paulo 84
Munich 81
Seattle 80
Tokyo 73
Shenyang 65
Helsinki 57
Des Moines 56
Shanghai 52
Verona 51
L’Aquila 48
Orem 48
Frankfurt am Main 47
Kunming 46
Rome 46
Columbus 45
Mountain View 43
Brussels 42
Hebei 42
Jiaxing 41
Montreal 41
Phoenix 41
Houston 35
Jinan 35
Philadelphia 35
Dong Ket 34
Chicago 33
Tianjin 33
Changsha 31
Johannesburg 31
Lappeenranta 30
Toronto 30
Stockholm 29
Zhengzhou 29
Brooklyn 28
Haiphong 27
Norwalk 27
Atlanta 25
Chennai 25
Pune 25
Warsaw 25
Da Nang 24
Buffalo 23
Denver 23
London 23
San Francisco 23
Pescara 22
Guangzhou 21
Hangzhou 21
Manchester 21
New Delhi 20
Rio de Janeiro 20
Brno 18
Ningbo 18
Ankara 17
Falkenstein 17
Assago 16
Belo Horizonte 16
Charlotte 16
Mexico City 16
Boston 15
Kitzingen 15
Brasília 14
Amman 13
Mumbai 13
Naples 13
Nuremberg 13
Poplar 13
Totale 19.326
Salva come PNG Salva come JPEG
Nome #
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 205
Aumento dei linfociti circolanti gamma-delta Vdelta1+ in corso di malattie infiammatorie intestinali 186
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 183
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 176
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 163
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 161
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 158
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 158
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 156
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 155
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 155
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 155
Evaluating the multivisceral involvement on adult-onset Still’s disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study 155
Prognostic factors of adult onset Still’s disease: analysis of 100 cases in 3 tertiary referral centers 153
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 151
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 149
Linfociti T Gamma-Delta (G/D) in pazienti con malattie infiammatorie intestinali (IBD) 146
Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis 145
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 144
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 143
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 142
Cardiovascular disease in primary sjögren’s syndrome 141
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 140
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. 138
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? 138
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 137
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 137
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 137
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 137
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. 135
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences 135
Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. 134
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 133
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 132
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 132
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 131
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 131
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 128
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 128
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 127
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 127
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 127
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis 127
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 126
Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization 125
Stem cell therapies for systemic sclerosis 125
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 125
Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis 125
Endothelial progenitor cells: Are they displaying a function in autoimmune disorders? 125
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 125
Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification 125
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 124
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 124
Comment on 'Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?' 123
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosi 123
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis 122
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 122
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 121
GAMMA/DELTA T CELL APOPTOSIS IN SYSTEMIC SCLEROSIS PATIENTS 121
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 121
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 120
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 120
Parenchymal lung disease in adult onset Still's disease: An emergent marker of disease severity - Characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients 120
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease 119
Combined approach to the initial stage raynaud’s phenomenon diagnosis by means of dynamic digital telehermograpy, capillaroscopy and pletismography. Preliminary findings. 119
Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. 119
Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis 119
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 119
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms 118
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 118
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 118
 T cells in placenta and skin: their different functions may support the paradigm of microchimerism in systemic sclerosi 117
Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? 117
Gamma-delta T cells are not involved in the natural and antibody-dependent cytotoxicity of peripheral blood mononuclear cells in inflammatory bowel disease. 117
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 117
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 116
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 116
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 116
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 116
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 116
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 116
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 115
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis 114
Variations of neuronal nitric oxide synthase in systemic sclerosis skin 114
DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. 114
Interleukin-9 and T helper type 9 cells in rheumatic diseases 114
Long-term Safety of Rituximab in Primary Sjögren Syndrome: The Experience of a Single Center 113
EFFICACY AND SAFETY OF RITUXIMAB TREATMENT IN EARLY PRIMARY SJOGREN'S SYNDROME: A CLINICAL, HISTOLOGICAL AND MOLECULAR STUDY 113
Interstitial lung disease in systemic sclerosis: current and future treatment. 113
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 112
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 112
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 112
Advanced diagnostic imaging and intervention in tendon diseases 112
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 111
The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational "real-life" study 111
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 111
FAS -670 gene promoter polymorphism confers susceptibility to systemic sclerosis 111
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al 111
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. 111
Is minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren׳s syndrome? Association between clinical, histopathological, and molecular features: A retrospective study 110
Totale 12.980
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.170
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.170
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.236 0 88 249 96 33 19 28 63 108 68 93 391
2022/20234.607 336 251 82 479 395 489 31 298 2.013 30 143 60
2023/20241.248 168 74 82 157 106 363 25 73 9 57 36 98
2024/20255.119 114 89 484 180 650 461 673 394 1.179 213 346 336
2025/202610.275 535 1.005 748 1.149 942 740 1.757 413 1.022 1.130 673 161
2026/2027738 387 351 0 0 0 0 0 0 0 0 0 0
Totale 29.620